Pinnacle Associates’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Pinnacle Associates’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.57M	Buy	12,266 +500	+4%	+$62.4K	0.02%	443
2025 Q4	$1.43M	Buy	11,766 +760	+7%	+$87.1K	0.02%	453
2025 Q3	$1.1M	Sell	11,006 -550	-5%	-$49.5K	0.01%	493
2025 Q2	$958K	Buy	11,556 +1,530	+15%	+$122K	0.01%	515
2025 Q1	$813K	Sell	10,026 -350	-3%	-$31.3K	0.01%	520
2024 Q4	$934K	Buy	10,376 +3,385	+48%	+$328K	0.01%	497
2024 Q3	$624K	Sell	6,991 -3,355	-32%	-$330K	0.01%	535
2024 Q2	$959K	Buy	10,346 +1,760	+20%	+$158K	0.02%	478
2024 Q1	$815K	Buy	8,586 +1,595	+23%	+$148K	0.01%	511
2023 Q4	$624K	Sell	6,991 -770	-10%	-$57.2K	0.01%	544
2023 Q3	$567K	Buy	7,761 +2,010	+35%	+$161K	0.01%	544
2023 Q2	$478K	Hold	5,751	–	–	0.01%	578
2023 Q1	$438K	Sell	5,751 -100	-2%	-$8.3K	0.01%	549
2022 Q4	$486K	Sell	5,851 -975	-14%	-$78.9K	0.01%	508
2022 Q3	$541K	Sell	6,826 -2,120	-24%	-$179K	0.01%	487
2022 Q2	$664K	Sell	8,946 -12,760	-59%	-$958K	0.01%	481
2022 Q1	$1.95M	Buy	21,706 +4,272	+25%	+$394K	0.03%	349
2021 Q4	$1.95M	Buy	17,434 +4,408	+34%	+$532K	0.03%	352
2021 Q3	$1.64M	Buy	13,026 +268	+2%	+$34.5K	0.03%	371
2021 Q2	$1.73M	Hold	12,758	–	–	0.03%	356
2021 Q1	$1.73M	Sell	12,758 -15	-0.1%	-$2.25K	0.03%	347
2020 Q4	$1.8M	Sell	12,773 -35	-0.3%	-$4.48K	0.04%	320
2020 Q3	$1.43M	Sell	12,808 -145	-1%	-$16.3K	0.03%	321
2020 Q2	$1.45M	Buy	12,953 +3,082	+31%	+$304K	0.04%	317
2020 Q1	$764K	Sell	9,871 -1,184	-11%	-$105K	0.02%	379
2019 Q4	$1.05M	Buy	11,055 +1,636	+17%	+$142K	0.02%	398
2019 Q3	$718K	Buy	9,419 +1,102	+13%	+$91.6K	0.02%	470
2019 Q2	$729K	Buy	8,317 +657	+9%	+$56K	0.02%	469
2019 Q1	$694K	Buy	7,660 +3,585	+88%	+$305K	0.02%	478
2018 Q4	$292K	Sell	4,075 -4,924	-55%	-$397K	0.01%	582
2018 Q3	$863K	Buy	+8,999	New	+$872K	0.02%	442

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Pinnacle Associates's XBI Position: Q1 2026 in Review

Pinnacle Associates increased its State Street SPDR S&P Biotech ETF (XBI) stake by 4.2% in Q1 2026, buying an estimated $62.4K and bringing the position to 12,266 shares worth $1.57M. The position accounts for 0.02% of the portfolio, ranked #443.

Pinnacle Associates first reported a position in XBI in Q3 2018 and has held it in 31 quarters since. The position peaked at $1.95M in Q4 2021. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Pinnacle Associates held 12,266 shares of State Street SPDR S&P Biotech ETF worth $1.57M as of Q1 2026.
Pinnacle Associates bought 500 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $62.4K.
State Street SPDR S&P Biotech ETF made up 0.02% of Pinnacle Associates's portfolio in Q1 2026, its #443 holding.
Pinnacle Associates first reported a position in State Street SPDR S&P Biotech ETF in Q3 2018 and has held it in 31 quarters since.
Pinnacle Associates's State Street SPDR S&P Biotech ETF position peaked at $1.95M in Q4 2021.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Pinnacle Associates's 13F filing for Q1 2026, filed 22 Apr 2026.